OBJECTIVE OUTCOME CRITERIA IN TRIALS OF ANTI-PARKINSONIAN THERAPY IN THE ELDERLY - SENSITIVITY, SPECIFICITY AND RELIABILITY OF MEASURES OF BRADYKINESIA AND HYPOKINESIA

被引:20
作者
BOWES, SG
CLARK, PK
CHARLETT, A
ONEILL, CJA
LEEMAN, AL
WELLER, C
NICHOLSON, PW
DESHMUKH, AA
DOBBS, SM
DOBBS, RJ
机构
[1] NORTHWICK PK HOSP & CLIN RES CTR,CLIN RES CTR,THERAPEUT ELDERLY RES GRP,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND
[2] NORTHWICK PK HOSP & CLIN RES CTR,CLIN RES CTR,MED STAT SECT,HARROW HA1 3UJ,MIDDX,ENGLAND
[3] NORTHWICK PK HOSP & CLIN RES CTR,CLIN RES CTR,DIV BIOENGN,HARROW HA1 3UJ,MIDDX,ENGLAND
[4] UNIV COLL & MIDDLESEX SCH MED,LONDON W1P 6DB,ENGLAND
[5] UNIV LONDON,LONDON WC1 1AX,ENGLAND
关键词
D O I
10.1111/j.1365-2125.1991.tb05533.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 We compare the sensitivity and specificity of chosen outcome criteria in a placebo-controlled, randomised cross-over study of the efficacy of maintenance therapy with the levodopa/carbidopa combination (Sinemet Plus) alone. Patients were characterised by having idiopathic Parkinsonism with no overt fluctuations in control in relation to individual doses of medication. 2 The effect of omission of a morning dose of maintenance therapy on simple timed tests of mobility and manual dexterity, and on distance/time parameters of gait was studied in fourteen patients (aged 64 to 88 years). Measurements made 2, 4 and 6 h after morning active and placebo treatments were standardised by taking the pre-treatment measurement on that day as baseline. 3 In a linear model, which allowed for the structure of the study, neither the total time taken by each patient to get up from a chair, walk an individually set distance, turn, return to and sit in the chair, nor the rate of progress at fastening the same set of buttons, was sensitive to the treatment effect. 4 Three of the gait parameters, free walking speed, mean stride length and mean double support time, were sensitive to the treatment effect. Correction for the speed of each walk, caused some reduction in the sensitivity of stride length to treatment effect, but that of double support time remained. Speed, and double support time or stride length, appeared to be complementary in defining the treatment effect. 5 The linear modelling revealed the complexity of the treatment effect. Although active treatment, by comparison with placebo, increased free walking speed (P = 0.019), the more levodopa found in the plasma following treatment, (P = 0.0005) and the greater the increment in the concentration of its peripheral metabolite, 3-O-methyldopa (P = 0.006), the less the beneficial effect. This model may reflect reduced uptake into the brain and/or an adverse effect of parent drug or a metabolite. 6 The specificity of free walking speed for the treatment effect was good, as was that of mean stride length, after it had been corrected for speed of each walk, and of mean double support time, after correction for speed and incorporation of the change in lying blood pressure accompanying treatment into the model. 7 The measurements of gait parameters were ranked according to reliability. If, as here, the walk were carried out six times following each treatment and the gait traces measured by hand, free walking speed would be of moderate reliability, but mean stride length and mean double support time of poor reliability. However, the signals generated by the gait analysis apparatus can now be measured directly by computer: computerised gait analysis may prove of adequate reliability, even in frail, elderly patients, for between subject comparisons, as well as being sensitive to and specific for treatment effect within subject.
引用
收藏
页码:295 / 304
页数:10
相关论文
共 20 条
  • [11] LEEMAN AL, 1989, CURRENT PROBLEMS NEU, V9, P319
  • [12] TREATMENT OF PARKINSONISM WITH LAEVO-DOPA
    MAWDSLEY, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1970, 1 (5692): : 331 - +
  • [13] McCullagh P., 1983, GEN LINEAR MODELS
  • [14] MINDHAM RHS, 1976, J CLIN PHARM S2, V3, P395
  • [15] THE ON OFF PHENOMENON IN PARKINSONS-DISEASE - RELATION TO LEVODOPA ABSORPTION AND TRANSPORT
    NUTT, JG
    WOODWARD, WR
    HAMMERSTAD, JP
    CARTER, JH
    ANDERSON, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (08) : 483 - 488
  • [16] 3-0-METHYLDOPA UPTAKE AND INHIBITION OF L-DOPA AT BLOOD-BRAIN-BARRIER
    WADE, LA
    KATZMAN, R
    [J]. LIFE SCIENCES, 1975, 17 (01) : 131 - 136
  • [17] QUALITATIVE AND QUANTITATIVE EVALUATION OF AMANTADINE IN TREATMENT OF PARKINSONS DISEASE
    WALKER, JE
    TOURTELLOTTE, WW
    SMITH, A
    POTVIN, AR
    ALBERS, JW
    HENDERSON, WG
    [J]. JOURNAL OF CHRONIC DISEASES, 1972, 25 (03): : 149 - +
  • [18] WELLER C, 1989, BIOTELEMETRY, V10, P575
  • [19] WINER BJ, 1971, STATISTICAL PRINCIPL, pCH4
  • [20] 1986, GLIM RELEASE 3 77 GE